Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alginos is an oral suspension containing sodium alginate (50 mg/ml) developed by TTY Biopharm. It is being investigated for the treatment of Laryngopharyngeal Reflux (LPR), a condition characterized by the backflow of gastric acid into the larynx and hypopharynx, leading to symptoms like hoarseness and throat pain. Sodium alginate is known for its effectiveness in the symptomatic treatment of gastroesophageal reflux, where it forms a protective raft on the gastric contents to prevent reflux. The ongoing clinical study aims to evaluate the efficacy and safety of Alginos in LPR patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alginos.